Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Kelly-Anne Phillips; Roger L Milne; Matti A Rookus; Mary B Daly; Antonis C Antoniou; Susan Peock; Debra Frost; Douglas F Easton; Steve Ellis; Michael L Friedlander; Saundra S Buys; Nadine Andrieu; Catherine Noguès; Dominique Stoppa-Lyonnet; Valérie Bonadona; Pascal Pujol; Sue Anne McLachlan; Esther M John; Maartje J Hooning; Caroline Seynaeve; Rob A E M Tollenaar; David E Goldgar; Mary Beth Terry; Trinidad Caldes; Prue C Weideman; Irene L Andrulis; Christian F Singer; Kate Birch; Jacques Simard; Melissa C Southey; Håkan L Olsson; Anna Jakubowska; Edith Olah; Anne-Marie Gerdes; Lenka Foretova; John L Hopper

doi:10.1200/JCO.2012.47.8313

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander, Saundra S Buys, Nadine Andrieu, Catherine Noguès, Dominique Stoppa-Lyonnet, Valérie Bonadona, Pascal Pujol, Sue Anne McLachlan, Esther M John, Maartje J Hooning, Caroline SeynaeveRob A E M Tollenaar, David E Goldgar, Mary Beth Terry, Trinidad Caldes, Prue C Weideman, Irene L Andrulis, Christian F Singer, Kate Birch, Jacques Simard, Melissa C Southey, Håkan L Olsson, Anna Jakubowska, Edith Olah, Anne-Marie Gerdes, Lenka Foretova, John L Hopper

130 Citationer (Scopus)

Abstract

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). Conclusion This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.

Originalsprog	Engelsk
Tidsskrift	Journal of Clinical Oncology
Vol/bind	31
Udgave nummer	25
Sider (fra-til)	3091-3099
Antal sider	9
ISSN	0732-183X
DOI	https://doi.org/10.1200/JCO.2012.47.8313
Status	Udgivet - 1 sep. 2013

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.1200/JCO.2012.47.8313

Citationsformater

Phillips, K-A., Milne, R. L., Rookus, M. A., Daly, M. B., Antoniou, A. C., Peock, S., Frost, D., Easton, D. F., Ellis, S., Friedlander, M. L., Buys, S. S., Andrieu, N., Noguès, C., Stoppa-Lyonnet, D., Bonadona, V., Pujol, P., McLachlan, S. A., John, E. M., Hooning, M. J., ... Hopper, J. L. (2013). Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Journal of Clinical Oncology, 31(25), 3091-3099. https://doi.org/10.1200/JCO.2012.47.8313

Phillips, K-A, Milne, RL, Rookus, MA, Daly, MB, Antoniou, AC, Peock, S, Frost, D, Easton, DF, Ellis, S, Friedlander, ML, Buys, SS, Andrieu, N, Noguès, C, Stoppa-Lyonnet, D, Bonadona, V, Pujol, P, McLachlan, SA, John, EM, Hooning, MJ, Seynaeve, C, Tollenaar, RAEM, Goldgar, DE, Terry, MB, Caldes, T, Weideman, PC, Andrulis, IL, Singer, CF, Birch, K, Simard, J, Southey, MC, Olsson, HL, Jakubowska, A, Olah, E, Gerdes, A-M, Foretova, L & Hopper, JL 2013, 'Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers', Journal of Clinical Oncology, bind 31, nr. 25, s. 3091-3099. https://doi.org/10.1200/JCO.2012.47.8313

@article{9667c5f1cbfa4aba87156fee8310fa65,

title = "Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers",

abstract = "Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). Conclusion This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.",

author = "Kelly-Anne Phillips and Milne, {Roger L} and Rookus, {Matti A} and Daly, {Mary B} and Antoniou, {Antonis C} and Susan Peock and Debra Frost and Easton, {Douglas F} and Steve Ellis and Friedlander, {Michael L} and Buys, {Saundra S} and Nadine Andrieu and Catherine Nogu{\`e}s and Dominique Stoppa-Lyonnet and Val{\'e}rie Bonadona and Pascal Pujol and McLachlan, {Sue Anne} and John, {Esther M} and Hooning, {Maartje J} and Caroline Seynaeve and Tollenaar, {Rob A E M} and Goldgar, {David E} and Terry, {Mary Beth} and Trinidad Caldes and Weideman, {Prue C} and Andrulis, {Irene L} and Singer, {Christian F} and Kate Birch and Jacques Simard and Southey, {Melissa C} and Olsson, {H{\aa}kan L} and Anna Jakubowska and Edith Olah and Anne-Marie Gerdes and Lenka Foretova and Hopper, {John L}",

year = "2013",

month = sep,

day = "1",

doi = "10.1200/JCO.2012.47.8313",

language = "English",

volume = "31",

pages = "3091--3099",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "25",

}

TY - JOUR

T1 - Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

AU - Phillips, Kelly-Anne

AU - Milne, Roger L

AU - Rookus, Matti A

AU - Daly, Mary B

AU - Antoniou, Antonis C

AU - Peock, Susan

AU - Frost, Debra

AU - Easton, Douglas F

AU - Ellis, Steve

AU - Friedlander, Michael L

AU - Buys, Saundra S

AU - Andrieu, Nadine

AU - Noguès, Catherine

AU - Stoppa-Lyonnet, Dominique

AU - Bonadona, Valérie

AU - Pujol, Pascal

AU - McLachlan, Sue Anne

AU - John, Esther M

AU - Hooning, Maartje J

AU - Seynaeve, Caroline

AU - Tollenaar, Rob A E M

AU - Goldgar, David E

AU - Terry, Mary Beth

AU - Caldes, Trinidad

AU - Weideman, Prue C

AU - Andrulis, Irene L

AU - Singer, Christian F

AU - Birch, Kate

AU - Simard, Jacques

AU - Southey, Melissa C

AU - Olsson, Håkan L

AU - Jakubowska, Anna

AU - Olah, Edith

AU - Gerdes, Anne-Marie

AU - Foretova, Lenka

AU - Hopper, John L

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). Conclusion This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.

AB - Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). Conclusion This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.

U2 - 10.1200/JCO.2012.47.8313

DO - 10.1200/JCO.2012.47.8313

M3 - Journal article

C2 - 23918944

SN - 0732-183X

VL - 31

SP - 3091

EP - 3099

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 25

ER -

Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater